

June 25, 2025

Company name: Astena Holdings Co., Ltd.
Name of representative: Satoshi Setoguchi, President & CEO
(Securities code: 8095; TSE Prime Market)
Inquiries: Naoki Enomoto, Executive Officer
(TEL: +81-3-3279-0481)

Astena Holdings Announces Change in Duties Assigned to One Director and Personnel Transfer Involving Another Individual

Astena Holdings Co., Ltd. (the "Company") hereby announces that it has resolved a change in duties assigned to one Director and a personnel transfer involving another individual at the Board of Directors meeting held today, as outlined below.

1. Change in duties assigned to one Director (as of July 1, 2025)

Name	New positions	Former positions
Keitaro Iwaki	Director, in charge of FC and Pharmaceutical Structural Reform, Fine Chemicals Business, and New Business; President & Representative Director, SPERA PHARMA, Inc.; President & CEO, SPERA NEXUS, Inc.; Chairperson of Board of Directors, IWAKI SEIYAKU CO., LTD.; Chairman, IWAKI SEIYAKU SAKURA FACTORY CO., LTD.	Director, in charge of FC and Pharmaceutical Business Structural Reform and New Business; President & Representative Director, SPERA PHARMA, Inc.; Chairperson of Board of Directors, IWAKI SEIYAKU CO., LTD.; Chairman, IWAKI SEIYAKU SAKURA FACTORY CO., LTD.

2. Personnel transfer (as of July 1, 2025)

Name	New positions	Former positions
Hirotooshi Naruse	Managing Executive Director, in charge of Pharmaceutical Business; Manager of FC and Pharmaceutical Business Structural Reform Office; Director, SPERA PHARMA, Inc.	Managing Executive Director, in charge of Pharmaceutical Business; Manager of FC and Pharmaceutical Business Structural Reform Office;